var data={"title":"Carfilzomib: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Carfilzomib: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/515810?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=carfilzomib-patient-drug-information\" class=\"drug drug_patient\">see &quot;Carfilzomib: Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14791719\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Kyprolis</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46539123\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Kyprolis</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14641045\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Proteasome Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14729214\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Hydrate with oral fluids (30 mL/kg) at least 48 hours prior to initiating cycle 1, as well as with 250 to 500 mL normal saline (or other appropriate IV fluid) before dosing (recommended) and after (if needed) administration during cycle 1 (continue oral and/or IV hydration in subsequent cycles if necessary); monitor for evidence of volume overload and adjust hydration based on individual needs. Consider antiviral prophylaxis for patients with a history of herpes zoster infection. Thromboprophylaxis is recommended when administering in combination with dexamethasone or lenalidomide plus dexamethasone.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Premedication:</i> When administering as monotherapy, premedicate with dexamethasone 4 mg orally or IV when infusing carfilzomib over 10 minutes or with dexamethasone 8 mg orally or IV when infusing carfilzomib over 30 minutes. When using combination therapy, administer the recommended dexamethasone dose (refer to prescribing information). Premedicate 30 minutes to 4 hours prior to all doses in cycle 1, and as needed with future cycles to reduce the incidence and severity of infusion reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Calculate dose using actual body surface area (BSA) at baseline. Patients with a BSA &gt;2.2 m<sup>2</sup> should be dosed based upon a maximum BSA of 2.2 m<sup>2</sup>. Dose adjustments for weight changes of &le;20% are not necessary, per manufacturer labeling. Continue until disease progression or unacceptable toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Multiple myeloma, relapsed/refractory (single-agent; 20/27 mg/m<sup>2</sup> regimen):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cycle 1: 20 mg/m<sup>2</sup> over 10 minutes on days 1 and 2; if tolerated, increase dose to 27 mg/m<sup>2</sup> over 10 minutes on days 8, 9, 15, and 16 of a 28-day treatment cycle</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cycles 2 to 12: 27 mg/m<sup>2</sup> over 10 minutes on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cycle 13 and beyond: 27 mg/m<sup>2</sup> over 10 minutes on days 1, 2, 15, and 16 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Multiple myeloma, relapsed/refractory (single-agent; 20/56 mg/m<sup>2</sup> regimen):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cycle 1: 20 mg/m<sup>2</sup> over 30 minutes on days 1 and 2; if tolerated, increase dose to 56 mg/m<sup>2</sup> over 30 minutes on days 8, 9, 15, and 16 of a 28-day treatment cycle.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cycles 2 to 12: 56 mg/m<sup>2</sup> over 30 minutes on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cycle 13 and beyond: 56 mg/m<sup>2</sup> over 30 minutes on days 1, 2, 15, and 16 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Multiple myeloma, relapsed/refractory (in combination with lenalidomide and dexamethasone) (Stewart 2015):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cycle 1: 20 mg/m<sup>2</sup> over 10 minutes on days 1 and 2; if tolerated, increase dose to 27 mg/m<sup>2</sup> over 10 minutes on days 8, 9, 15, and 16 of a 28-day treatment cycle.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cycles 2 to 12: 27 mg/m<sup>2</sup> over 10 minutes on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cycles 13 to 18: 27 mg/m<sup>2</sup> over 10 minutes on days 1, 2, 15, and 16 of a 28-day treatment cycle; beginning with cycle 19, lenalidomide and dexamethasone may be continued (until disease progression or unacceptable toxicity) without carfilzomib.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Multiple myeloma, relapsed/refractory (in combination with dexamethasone):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cycle 1: 20 mg/m<sup>2</sup> over 30 minutes on days 1 and 2; if tolerated, increase dose to 56 mg/m<sup>2</sup> over 30 minutes on days 8, 9, 15, and 16 of a 28-day treatment cycle.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cycle 2 and beyond: 56 mg/m<sup>2</sup> over 30 minutes on days 1, 2, 8, 9, 15, and 16 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Waldenstr&ouml;m macroglobulinemia (off-label use):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Induction (Treon 2014):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cycle 1: 20 mg/m<sup>2</sup> over 20 minutes on days 1, 2, 8, and 9 of a 21-day treatment cycle (in combination with dexamethasone and rituximab)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cycles 2 to 6: 36 mg/m<sup>2</sup> over 30 minutes on days 1, 2, 8, and 9 of a 21-day treatment cycle (in combination with dexamethasone and rituximab)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance (started 8 weeks after completion of induction therapy in patients with stable disease or better response): 36 mg/m<sup>2</sup> on days 1 and 2 every 8 weeks for 8 cycles (in combination with dexamethasone and rituximab) (Treon 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14729217\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14729212\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">The International Myeloma Working Group recommends the use of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (preferred) or the Modification of Diet in Renal Disease (MDRD) formula to evaluate renal function estimation in multiple myeloma patients with a stable serum creatinine (Dimopoulos 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Preexisting renal impairment:</b> No initial dosage adjustment necessary (Badros 2013; Quach 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: No initial dosage adjustment necessary (Quach 2017). Administer after dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">The International Myeloma Working Group Recommendations suggest that (based on evaluating the 20/27 mg/m<sup>2</sup> dose), carfilzomib may be safely administered to patients with a CrCl &ge;15 mL/minute; although there is less data, carfilzomib may also be administered to patients with CrCl &lt;15 mL/minute (Dimopoulos 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal toxicity during treatment:</b> Serum creatinine &ge;2 times baseline, CrCl &lt;15 mL/minute or CrCl decreases to &le;50% of baseline, or patient requires dialysis: Withhold dose and monitor renal function. If renal toxicity is due to carfilzomib, resume dosing when renal function has improved to within 25% of baseline; resume with a reduced dose by 1 dose level (see Dosing- Adjustment for Toxicity for dose level reductions). If toxicity is not due to carfilzomib, restart at the discretion of the prescriber.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14729213\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Preexisting hepatic impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild (bilirubin &gt;1 to 1.5 times ULN or AST &gt; ULN) or moderate (bilirubin &gt;1.5 to 3 times ULN) impairment: Reduce dose to 75% of recommended dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe (bilirubin &gt; 3 times ULN) impairment: There are no dosage adjustments provided in the manufacturer's labeling (the pharmacokinetics of carfilzomib have not been evaluated in patients with bilirubin &gt;3 times ULN and any AST).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatotoxicity during treatment: </b>Grade 3 or 4 elevation of bilirubin, transaminases, or other liver abnormalities: Withhold dose until resolved or at baseline. After resolution, if appropriate to reinitiate, consider restarting at 1 dose level reduction (see Dosing: Adjustment for Toxicity for dose level reductions) with frequent monitoring of hepatic function.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20344399\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <i>ASCO Guidelines for appropriate chemotherapy dosing in obese adults with cancer: </i> In general, utilize patient's actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs 2012). <b>Note:</b> According to the manufacturer, patients with a body surface area (BSA) &gt;2.2 m<sup>2</sup> should be dosed based upon a maximum BSA of 2.2 m<sup>2</sup>; dose adjustments for weight changes of &le;20% are not necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14729215\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Carfilzomib dose level reductions for toxicity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If initial dose is <b>27</b> mg/m<sup>2</sup>:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">First dose reduction: 20 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Second dose reduction: 15 mg/m<sup>2</sup>; if toxicity persists on 15 mg/m<sup>2</sup> dose, discontinue carfilzomib</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If initial dose is<b> 56</b> mg/m<sup>2</sup>:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">First dose reduction: 45 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Second dose reduction: 36 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Third dose reduction: 27 mg/m<sup>2</sup>; if toxicity persists on 27 mg/m<sup>2</sup> dose, discontinue carfilzomib</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hematologic toxicity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>ANC  &lt;500/mm<sup>3</sup>:</i>   Withhold dose; continue at same dose level if ANC recovers to &ge;500/mm<sup>3</sup>.  For subsequent ANC levels &lt;500/mm<sup>3</sup>, withhold dose and consider reducing dose by 1 dose level when ANC &ge;500/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Neutropenic fever (ANC &lt;500/mm<sup>3</sup> with an oral temperature &gt;38.5&deg;C or 2 consecutive readings of &gt;38&deg;C for 2 hours):</i> Withhold dose; if ANC recovers to baseline and fever resolves, resume at the same dose level.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Platelets: &lt;10,000/mm<sup>3</sup> or evidence of bleeding with thrombocytopenia:</i>  Withhold dose; continue at same dose level if platelets recover to &ge;10,000/mm<sup>3</sup> and bleeding is controlled. For subsequent platelet levels &lt;10,000/mm<sup>3</sup>, withhold dose and consider reducing dose by 1 dose level when platelets &ge;10,000/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nonhematologic toxicity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Grade 3 or 4 nonhematologic toxicities:</i> Withhold dose until resolved or at baseline. After resolution, consider restarting the next scheduled treatment at 1 dose level reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cardiac:</i> Grade 3 or 4, new-onset or worsening of heart failure, decreased left ventricular function, or myocardial ischemia: Withhold dose until resolved or at baseline. After resolution, if considered appropriate to reinitiate, consider restarting at 1 dose level reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hemorrhage or symptoms of blood loss:</i> Reduce dose or withhold treatment as clinically appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hypertension, severe or life-threatening:</i> If hypertension cannot be adequately controlled, withhold dose and evaluate. After resolution, consider if appropriate to reinitiate based on risk versus benefit.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pulmonary toxicity</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Acute respiratory distress syndrome, acute respiratory failure, and acute diffuse infiltrative pulmonary disease (drug-induced): Discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pulmonary hypertension: Withhold dose until resolved or at baseline. After resolution, consider if appropriate to reinitiate based on risk versus benefit.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Grade 3 or 4 dyspnea: Withhold dose until resolved or at baseline. After resolution, consider if appropriate to reinitiate based on risk versus benefit.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Tumor lysis syndrome:</i> Interrupt treatment until resolved.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14729234\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kyprolis: 30 mg (1 ea); 60 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14729167\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49410945\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution Reconstituted, Intravenous:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Kyprolis: 10 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14729226\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Administer over 10 or 30 minutes depending on the carfilzomib dose regimen (see Dosing). Do not administer as an IV push or bolus. Hydrate with oral fluids (30 mL/kg) at least 48 hours prior to initiating cycle 1, as well as with 250 to 500 mL NS (or other appropriate IV fluid) prior to (recommended) and after (if needed) each dose in cycle 1; continue oral and/or IV hydration in subsequent cycles (if necessary). Flush line immediately before and after carfilzomib with NS or D<sub>5</sub>W. Do not administer with other medications.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">When administering as monotherapy, premedicate with dexamethasone 4 mg orally or IV when infusing carfilzomib over 10 minutes or with dexamethasone 8 mg orally or IV when infusing carfilzomib over 30 minutes. When using combination therapy, administer the recommended dexamethasone dose (refer to prescribing information). Premedicate 30 minutes to 4 hours prior to all doses in cycle 1, and as needed with future cycles to reduce the incidence and severity of infusion reaction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130924\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).    </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14641319\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Multiple myeloma, relapsed/refractory:</b> Treatment (monotherapy) of relapsed or refractory multiple myeloma in patients who have received 1 or more lines of therapy; treatment of relapsed or refractory multiple myeloma (in combination with dexamethasone or lenalidomide plus dexamethasone) in patients who have received 1 to 3 prior lines of therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46901207\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Waldenstr&ouml;m macroglobulinemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14729165\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Carfilzomib may be confused with bortezomib, ixazomib</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49210440\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&ge;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (15% to 42%), peripheral edema (20% to 21%), chest pain (3% to 21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (40% to 58%), chills (12% to 38%), headache (24% to 33%), insomnia (13% to 29%), dizziness (11% to 29%), hypoesthesia (Siegel 2013), peripheral neuropathy (Siegel 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (35% to 54%), vomiting (17% to 33%), diarrhea (25% to 27%), anorexia (15% to 21%), constipation (Siegel 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Thrombocytopenia (37% to 54%; &ge; grade 3: 25% to 54%), anemia (42% to 49%, &ge; grade 3: 24% to 29%), lymphocytopenia (14% to 33%; &ge; grade 3: 12% to 33%), leukopenia (Siegel 2013), neutropenia (Siegel 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (19% to 21%), muscle spasm (10% to 21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (17% to 25%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (34% to 58%), cough (22% to 33%), upper respiratory tract infection (19% to 21%), pneumonia (Siegel 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (30% to 58%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Deep vein thrombosis (&le;2%), pulmonary embolism (&le;2%), pulmonary hypertension (1%), ischemic heart disease (Siegel 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Paresthesia (Siegel 2013), peripheral sensory neuropathy (Siegel 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypercalcemia (Siegel 2013), hyponatremia (Siegel 2012), hypophosphatemia (Siegel 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Febrile neutropenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal insufficiency (10%), acute renal failure (more common in patients with advanced relapsed and refractory multiple myeloma [Siegel 2013]), renal failure (Siegel 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cardiac failure, hypotension, thromboembolic complications</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Anxiety, intracranial hemorrhage, pain, voice disorder</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Erythema, hyperhidrosis, pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperglycemia, hyperkalemia, hyperuricemia, hypoalbuminemia, hypocalcemia, hypokalemia, hypomagnesemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain, dyspepsia, gastrointestinal hemorrhage, toothache, upper abdominal pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hemorrhage, pulmonary hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hepatic failure, increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza, sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Infusion site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia, limb pain, musculoskeletal chest pain, musculoskeletal pain, myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision, cataract</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchitis, bronchopneumonia, epistaxis, nasopharyngitis, oropharyngeal pain, pulmonary edema, pulmonary infection, respiratory tract infection, rhinitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Multiorgan failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Cardiomyopathy (restrictive), gastrointestinal perforation, hemolytic-uremic syndrome, immune thrombocytopenia, interstitial pulmonary disease, myocardial infarction (Siegel 2012), pericarditis, peripheral motor neuropathy (Siegel 2013), pneumonitis, pulmonary disease, respiratory distress syndrome (acute), reversible posterior leukoencephalopathy syndrome, tumor lysis syndrome (Siegel 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14729173\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer's US labeling</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Hypersensitivity to carfilzomib or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14729174\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Thrombocytopenia (including grade 4) was observed in patients receiving carfilzomib, with platelet nadirs occurring between day 8 and day 15 of each 28-day treatment cycle, and recovery to baseline by the start of the next cycle. Monitor platelets closely and adjust dose or withhold therapy if necessary. Hemorrhage due to thrombocytopenia may occur. Anemia, lymphopenia, leukopenia, and neutropenia were also observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: Death caused by cardiac arrest has occurred within 24 hours of administration. Carfilzomib has been associated with new-onset or worsening of heart failure (HF), pulmonary edema, decreased left ventricular ejection fraction (LVEF), restrictive cardiomyopathy, myocardial ischemia, and MI (including fatalities). Some events occurred in patients with normal ventricular function at baseline. Cardiac events typically were observed throughout the course of therapy. Patients &ge;75 years of age have an increased risk of heart failure. Monitor closely for cardiac complications and for volume overload (due to pretreatment hydration), particularly in patients at risk for HF; withhold carfilzomib therapy for grade 3 or 4 cardiac events until recovery. Patients with New York Heart Association Class III and IV heart failure, recent MI (within 3 to 6 months), and conduction abnormalities, angina, or arrhythmias not managed by medication were excluded from clinical trials and may be at increased risk for cardiac complications; evaluate with a comprehensive medical assessment prior to initiation and closely monitor.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemorrhage: Serious or fatal cases of hemorrhage have been reported, including GI, intracranial, and pulmonary hemorrhage and epistaxis. Bleeding may be spontaneous; intracranial hemorrhage has occurred without trauma. Hemorrhage has been reported in patients with and without low platelets and has also been reported in patients who were not receiving anticoagulation or antiplatelet therapy. Monitor for signs/symptoms of hemorrhage and promptly evaluate symptoms of blood loss. Reduce dose or withhold treatment as clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Hepatic failure, including fatal cases, has been reported rarely. Increased transaminases and hyperbilirubinemia have also been observed. Interrupt therapy with grade 3 or higher hepatic toxicity until resolved or recovered to baseline (may require dose reduction if appropriate to reinitiate); monitor liver enzymes regularly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension: Hypertension has occurred with use; hypertensive crisis and hypertensive emergency have also been reported (some events were fatal). Control hypertension prior to initiating carfilzomib. Monitor blood pressure regularly throughout therapy; if hypertension cannot be adequately controlled, interrupt carfilzomib therapy and evaluate; assess risks versus benefits when determining to restart treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: May occur immediately following or within 24 hours of carfilzomib infusion; may be life-threatening. Symptoms have included fever, chills, arthralgia, myalgia, flushing, facial edema, vomiting, weakness, dyspnea, hypotension, syncope, chest tightness, or angina. To lessen the incidence and intensity of infusion reactions, administer dexamethasone prior to drug administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Posterior reversible encephalopathy syndrome: Posterior reversible encephalopathy syndrome (PRES) has been reported rarely with use; symptoms include seizure, headache, lethargy, confusion, blindness, altered consciousness, hypertension, and other visual/neurological disturbances. Discontinue therapy if PRES diagnosis is suspected; the safety of reinitiating therapy after PRES diagnosis is not known.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary toxicities: Acute respiratory distress syndrome (ARDS), acute respiratory failure, and acute diffuse-infiltrative pulmonary disease (eg, pneumonitis and interstitial lung disease) have occurred in a small number of patients (some events were fatal); discontinue therapy if any of these drug-induced pulmonary toxicities occur. In clinical trials, pulmonary arterial hypertension (PAH) was observed (including grade 3 or higher events); perform cardiac imaging or other testing as appropriate, and withhold carfilzomib until PAH is resolved or returns to baseline. Dyspnea (including grade 3 or higher events) has been reported; monitor closely. Withhold carfilzomib for grade 3 or 4 dyspnea until pulmonary symptom resolution or return to baseline.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal toxicity: Renal toxicity (eg, renal insufficiency, acute renal failure, renal failure) has been reported with carfilzomib; some events have been fatal. Acute renal failure was observed more frequently in patients receiving carfilzomib monotherapy for advanced relapsed/refractory multiple myeloma; renal failure risk is greater when patients have a baseline reduced CrCl. Monitor renal function closely; may require therapy interruption or dose reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic microangiopathy: Thrombotic microangiopathy, including cases of thrombocytopenic thrombotic purpura/hemolytic uremic syndrome (TTP/HUS) has been reported (some fatal); monitor for signs/symptoms. Interrupt therapy if TTP/HUS diagnosis is suspected and manage appropriately (eg, plasma exchange as clinically necessary). If TTP/HUS diagnosis is excluded, may consider reinitiating therapy; the safety of restarting carfilzomib after a TTP/HUS diagnosis is not known.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events: Venous thromboembolism (eg, deep vein thrombosis and pulmonary embolism) has been observed, particularly when used as part of combination therapy with dexamethasone or with lenalidomide plus dexamethasone. Thromboprophylaxis is recommended with combination therapy, and should be based on patients&rsquo; underlying risk factors, treatment regimen, and clinical status. Due to risk of thrombosis with hormonal contraception, consider an alternative method of effective contraception during combination treatment of carfilzomib with dexamethasone or lenalidomide plus dexamethasone.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: Tumor lysis syndrome (TLS), including fatalities, has been observed. TLS risk is increased in multiple myeloma patients with a high tumor burden. Adequately hydrate patients prior to carfilzomib therapy and monitor closely for signs and symptoms of TLS; consider use of antihyperuricemic agents. If TLS occurs, interrupt treatment until resolved.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Concurrent drug therapy issues:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Combination therapy toxicity: An increased incidence of serious and fatal adverse events was observed in a clinical trial comparing the combination of carfilzomib, melphalan, and prednisone (KMP) to bortezomib, melphalan, and prednisone (VMP) for the treatment of newly diagnosed multiple myeloma (MM) in transplant-ineligible patients. Cardiac failure, hypertension, acute renal failure, and dyspnea were observed more frequently in the KMP arm. KMP is not an approved carfilzomib combination regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection: Vials contain the excipient cyclodextrin (sulfobutyl ether beta-cyclodextrin), which may accumulate in patients with renal insufficiency, although the clinical significance of this finding is uncertain (Luke 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14878017\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of P-glycoprotein/ABCB1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14878015\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=86042&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Carfilzomib may enhance the thrombogenic effect of Estrogen Derivatives (Contraceptive).  Management: Consider alternative, non-hormonal methods of contraception in patients requiring therapy with carfilzomib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Carfilzomib may enhance the thrombogenic effect of Progestins (Contraceptive).  Management: Consider alternative, non-hormonal methods of contraception in patients requiring therapy with carfilzomib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14729170\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Based on the mechanism of action, adverse fetal events would be expected to occur with use in pregnant women. Females and males of reproductive potential are advised to avoid pregnancy during therapy; women of reproductive potential should abstain from sexual activity or use effective contraception during treatment and for at least 30 days following therapy completion. Male patients of reproductive potential should abstain from sexual activity or use effective contraception during treatment and for at least 90 days following therapy completion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14729172\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if carfilzomib is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother and the health benefits of breastfeeding. The appropriate timing to restart breastfeeding after treatment discontinuation should be determined with the health care provider.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14729229\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelets (monitor frequently throughout therapy), serum potassium levels regularly during treatment, renal function, pulmonary function (with new or worsening pulmonary symptoms), liver function tests, blood pressure (regularly during treatment in all patients). Signs/symptoms of infusion-related reactions, congestive heart failure, tumor lysis syndrome, peripheral neuropathy, posterior reversible encephalopathy syndrome, thrombocytopenic thrombotic purpura/hemolytic uremic syndrome, and venous thromboembolic events. Monitor for evidence of volume overload due to pre- and posthydration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14729203\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Carfilzomib inhibits proteasomes, which are responsible for intracellular protein homeostasis. Specifically, it is a potent, selective, and irreversible inhibitor of chymotrypsin-like activity of the 20S proteasome, leading to cell cycle arrest and apoptosis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14729205\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: 28 L; penetrates all tissues extensively except the brain (Kortuem 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 97%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Rapid and extensive; peptidase cleavage and epoxide hydrolysis; minimal metabolism through cytochrome P450-mediated mechanisms</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Doses &ge;15 mg/m<sup>2</sup>: &le;1 hour on day 1 of cycle 1</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~25%, primarily as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570445\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Kyprolis Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (1): $1,352.42</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (1): $2,704.85</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25576764\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Kyprolis (AR, AT, BB, BR, CO, CR, CZ, DE, DK, DO, EE, FI, FR, GB, GT, HK, HN, HR, IE, IL, IS, JP, KR, LT, NI, NO, PA, PL, PT, RO, SG, SK, SV, TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alsina M, Trudel S, Furman RR, et al. A phase 1 single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. <i>Clin Cancer Res</i>. 2012;18(17):4830-4840.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/22761464/pubmed\" target=\"_blank\" id=\"22761464\">22761464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Badros AZ, Vij R, Martin T, et al. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. <i>Leukemia. </i>2013;27(8):1707-1714.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/23364621/pubmed\" target=\"_blank\" id=\"23364621\">23364621</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dimopoulos MA, Moreau P, Palumbo A, et al; ENDEAVOR investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomized, phase 3, open-label, multicenter study. <i>Lancet Oncol</i>. 2016;17(1):27-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/26671818/pubmed\" target=\"_blank\" id=\"26671818\">26671818</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. <i>J Clin Oncol.</i> 2016;34(13):1544-1557.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/26976420/pubmed\" target=\"_blank\" id=\"26976420\">26976420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i> J Clin Oncol</i>. 2012; 30(13):1553-1561.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khan ML and Stewart AK. Carfilzomib: A novel second-generation proteasome inhibitor. <i>Future Oncol</i>. 2011; 7(5):607-612.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/21568676/pubmed\" target=\"_blank\" id=\"21568676\">21568676</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kortuem KM and Stewart AK. Carfilzomib. <i>Blood.</i> 2013;121(6):893-897.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/23393020/pubmed\" target=\"_blank\" id=\"23393020\">23393020</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kyprolis (carfilzomib) [prescribing information]. Thousand Oaks, CA: Onyx Pharmaceuticals Inc; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kyprolis (carfilzomib) [product monograph]. Mississauga, Ontario, Canada: Amgen Canada Inc; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Luke DR, Tomaszewski K, Damle B, Schlamm HT. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). <i>J Pharm Sci</i>. 2010;99(8):3291-3301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/20213839/pubmed\" target=\"_blank\" id=\"20213839\">20213839</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Connor OA, Stewart AK, Vallone M, et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. <i>Clin Cancer Res</i>. 2009; 15(22):7085-7091.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/19903785/pubmed\" target=\"_blank\" id=\"19903785\">19903785</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parlati F, Lee SJ, Aujay M, et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. <i>Blood</i>. 2009; 114(16):3439-3447.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/19671918/pubmed\" target=\"_blank\" id=\"19671918\">19671918</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Quach H, White D, Spencer A, et al. Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study. <i>Cancer Chemother Pharmacol</i>. 2017;79(6):1067-1076.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/28424963/pubmed\" target=\"_blank\" id=\"28424963\">28424963</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. <i>Haematologica</i>. 2013;98(11):1753-1761.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/23935022/pubmed\" target=\"_blank\" id=\"23935022\">23935022</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siegel D, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. <i>Blood</i>. 2012;120(14):2817-2825.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/22833546/pubmed\" target=\"_blank\" id=\"22833546\">22833546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. <i>N Engl J Med</i>. 2015;372(2):142-152.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/25482145/pubmed\" target=\"_blank\" id=\"25482145\">25482145</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24859363\"></a>Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom&rsquo;s macroglobulinemia. <i>Blood.</i> 2014;124(4):503-510.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/24859363/pubmed\" target=\"_blank\" id=\"24859363\">24859363</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vij R, Siegel DS, Jagannath S, et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. <i>Br J Haematol.</i> 2012;158(6):739-748.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/22845873/pubmed\" target=\"_blank\" id=\"22845873\">22845873</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. <i>Blood</i>. 2012; 119(24):5661-5670.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/22555973/pubmed\" target=\"_blank\" id=\"22555973\">22555973</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zangari M, Aujay M, Zhan F, et al. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. <i>Eur J Haematol</i>. 2011; 86(6):484-487.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carfilzomib-drug-information/abstract-text/21477075/pubmed\" target=\"_blank\" id=\"21477075\">21477075</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 86042 Version 124.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F14791719\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F46539123\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F14641045\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F14729214\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F14729217\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F14729212\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F14729213\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20344399\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F14729215\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F14729234\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F14729167\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F49410945\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F14729226\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130924\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F14641319\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F46901207\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F14729165\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F49210440\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F14729173\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F14729174\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F14878017\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F14878015\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14729170\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F14729172\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F14729229\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F14729203\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F14729205\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16570445\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F25576764\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/86042|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=carfilzomib-patient-drug-information\" class=\"drug drug_patient\">Carfilzomib: Patient drug information \t</a></li></ul></div></div>","javascript":null}